Nada Arwa, Jetton Jennifer G
Division of Nephrology, Department of Pediatrics, Le Bonheur Children's Hospital & Saint Jude Research Hospital, The University of Tennessee Health Science Center, TN, Memphis, USA.
Division of Nephrology, Department of Pediatrics, Stead Family Children's Hospital, The University of Iowa, IA, Iowa, USA.
Pediatr Nephrol. 2021 Aug;36(8):2227-2255. doi: 10.1007/s00467-020-04800-3. Epub 2020 Nov 27.
Onco-nephrology has been a growing field within the adult nephrology scope of practice. Even though pediatric nephrologists have been increasingly involved in the care of children with different forms of malignancy, there has not been an emphasis on developing special expertise in this area. The fast pace of discovery in this field, including the development of new therapy protocols with their own kidney side effects and the introduction of the CD19-targeted chimeric antigen receptor T cell (CAR-T) therapy, has introduced new challenges for general pediatric nephrologists because of the unique effects of these treatments on the kidney. Moreover, with the improved outcomes in children receiving cancer therapy come an increased number of survivors at risk for chronic kidney disease related to both their cancer diagnosis and therapy. Therefore, it is time for pediatric onco-nephrology to take its spot on the expanding subspecialties map in pediatric nephrology.
肿瘤肾脏病学已成为成人肾脏病学实践范围内一个不断发展的领域。尽管儿科肾脏病学家越来越多地参与到患有不同形式恶性肿瘤儿童的护理工作中，但该领域尚未强调发展专门的专业知识。该领域的快速发展，包括开发出有自身肾脏副作用的新治疗方案以及引入靶向CD19的嵌合抗原受体T细胞（CAR-T）疗法，由于这些治疗对肾脏的独特影响，给普通儿科肾脏病学家带来了新的挑战。此外，随着接受癌症治疗的儿童预后改善，因癌症诊断和治疗而面临慢性肾脏病风险的幸存者数量增加。因此，儿科肿瘤肾脏病学是时候在儿科肾脏病学不断扩展的亚专业版图中占据一席之地了。
Zotero 插件